Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of cebranopadol for cancer-related pain after KF6005/07
NL-OMON41264Phase 3Withdrawn
- Sponsor
- Grünenthal GmbH
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cebranopadol in cancer pain, sponsored by Grünenthal GmbH. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Mar 2014; status: withdrawn.
02
Drugs
cebranopadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NL-OMON41264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41264.